02Sep
08Dec
From Conquering COVID-19 to Curing Cancer, New York City Charts the Future of Life Sciences
For the past 25 years, the public and private sectors have worked together to establish New York City as a global leader in life sciences research and innovation. Thanks to that coordinated effort, the city was able to respond to COVID-19 efficiently and effectively, becoming a model for other urban areas as COVID-19 cases peaked across the U.S.—and showcasing a burgeoning life sciences industry in the city that’s poised for future growth... New York life sciences companies continue to step...
30Sep
XYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery
Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Read more >>
16Sep
Patient-Derived Organoids Transform Precision Medicine
Advances in cell culture techniques don’t just mean more accurate models, but more personal ones. For decades scientists have been trying to figure out how to grow cells, especially diseased ones, directly from patients, not only to better understand the mechanisms at play, but also to determine the best approach to cure or correct the malfunction. Today, scientists can grow human tumors in a variety of designer mice, some with human immune systems. Read more >>
27Aug
XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Read more >>
21Aug
4th Annual IPF Summit
Xylyx Bio. to speak at the 4th Annual IPF Summer. Read more >>
28May
Xylyx Bio releases advanced disease model system to improve cancer drug discovery
Xylyx Bio, a leader in predictive disease models, today announced the release of its IN SITE™ Metastasis Kit, a highly physiologic system that contains complex site-specific microenvironments to provide scientists with much-needed insight into cancer disease biology and the efficacy of drug candidates. Read more >>
20May
Interview with John O’Neil, Chief Scientific Officer of Xylyx
An inspiration and candid conversation between Dr. Mayasari Lim and upcoming 3DHEALS2020 speaker John O’Neil, Chief Scientific Officer of Xylyx, a New York-based startup focusing on creating the perfect cell environment for a variety of biotech process including biofabrication/bioprinting, and tissue engineering. Read more >>
16Apr
Xylyx Bio offers advanced lung models to accelerate COVID-19-related drug development
Xylyx Bio, a pioneer in advanced biological systems for drug development, today announced availability of products that recreate the lung environment in vitro to provide a predictive model that brings much-needed insight into the efficacy of COVID-19-related drug candidates. Read more >>
14Feb